Patient demographics
| . | . | Checkpoint blockade . | . | |
|---|---|---|---|---|
| . | Total n = 33 (%) . | None/post-CAR T cell n = 18 (55) . | Prior to CAR T cell n = 15 (45) . | P . |
| Age, y | ||||
| Median (range) | 32 (18-46) | 30 (19-46) | 35 (18-40) | .73* |
| Stage | ||||
| I | 8 (24) | 5 (28) | 3 (20) | .68† |
| II | 8 (24) | 3 (17) | 5 (33) | |
| III | 7 (21) | 6 (33) | 1 (7) | |
| IV | 10 (30) | 4 (22) | 6 (40) | |
| Eastern Cooperative Oncology Group performance status | ||||
| 0 | 14 (42) | 8 (44) | 6 (40) | .61† |
| 1 | 17 (52) | 8 (44) | 9 (60) | |
| 2 | 1 (3) | 1 (6) | — | |
| 3 | 1 (3) | 1 (6) | — | |
| Bulky disease | ||||
| No | 19 (58) | 10 (56) | 9 (60) | >.99‡ |
| Yes | 14 (42) | 8 (44) | 6 (40) | |
| Prior radiation therapy | ||||
| No | 11 (33) | 8 (44) | 3 (20) | .27‡ |
| Yes | 22 (67) | 10 (56) | 12 (80) | |
| Prior auto | ||||
| No | 23 (70) | 15 (83) | 8 (53) | .13‡ |
| Yes | 10 (30) | 3 (17) | 7 (47) | |
| No. of prior lines of therapy | ||||
| Median (range) | 3 (1-9) | 3 (1-7) | 4 (3-9) | .04‡ |
| Restaging post-CAR T cell | ||||
| PD | 7 (21) | 5 (28) | 2 (13) | .29† |
| ORR | 25 (76) | 13 (72) | 12 (80) | |
| PR | 3 (9) | 2 (11) | 1 (7) | |
| CR | 22 (67) | 11 (61) | 11 (73) | |
| Missing | 1 (3) | 0 (0) | 1 (7) | |
| Response to checkpoint | ||||
| PD | 7 (21) | 1 (6) | 6 (40) | .23† |
| SD | 1 (3) | — | 1 (7) | |
| ORR | 9 (27) | 3 (17) | 6 (40) | |
| PR | 2 (6) | — | 2 (13) | |
| CR | 7 (21) | 3 (17) | 4 (27) | |
| Missing | 16 (48) | 14 (78) | 2 (13) | |
| CRS, any grade§ | ||||
| No | 4 (12) | 1 (6) | 3 (20) | .31‡ |
| Yes | 29 (88) | 17 (94) | 12 (80) | |
| CRS grade ≥3§ | ||||
| No | 31 (94) | 16 (89) | 15 (100) | .49‡ |
| Yes | 2 (6) | 2 (11) | — | |
| NT, any grade§ | ||||
| No | 20 (61) | 11 (61) | 9 (60) | >.99‡ |
| Yes | 13 (39) | 7 (39) | 6 (40) | |
| NT grade ≥3§ | ||||
| No | 24 (72) | 13 (72) | 11 (73) | >.99‡ |
| Yes | 9 (27) | 5 (28) | 4 (27) | |
| Immune mediated toxicity | ||||
| No | 26 (79) | 11 (61) | 15 (100) | >.99‡ |
| Yes | — | — | — | |
| Missing | 7 (21) | 7 (39) | 0 (0) | |
| . | . | Checkpoint blockade . | . | |
|---|---|---|---|---|
| . | Total n = 33 (%) . | None/post-CAR T cell n = 18 (55) . | Prior to CAR T cell n = 15 (45) . | P . |
| Age, y | ||||
| Median (range) | 32 (18-46) | 30 (19-46) | 35 (18-40) | .73* |
| Stage | ||||
| I | 8 (24) | 5 (28) | 3 (20) | .68† |
| II | 8 (24) | 3 (17) | 5 (33) | |
| III | 7 (21) | 6 (33) | 1 (7) | |
| IV | 10 (30) | 4 (22) | 6 (40) | |
| Eastern Cooperative Oncology Group performance status | ||||
| 0 | 14 (42) | 8 (44) | 6 (40) | .61† |
| 1 | 17 (52) | 8 (44) | 9 (60) | |
| 2 | 1 (3) | 1 (6) | — | |
| 3 | 1 (3) | 1 (6) | — | |
| Bulky disease | ||||
| No | 19 (58) | 10 (56) | 9 (60) | >.99‡ |
| Yes | 14 (42) | 8 (44) | 6 (40) | |
| Prior radiation therapy | ||||
| No | 11 (33) | 8 (44) | 3 (20) | .27‡ |
| Yes | 22 (67) | 10 (56) | 12 (80) | |
| Prior auto | ||||
| No | 23 (70) | 15 (83) | 8 (53) | .13‡ |
| Yes | 10 (30) | 3 (17) | 7 (47) | |
| No. of prior lines of therapy | ||||
| Median (range) | 3 (1-9) | 3 (1-7) | 4 (3-9) | .04‡ |
| Restaging post-CAR T cell | ||||
| PD | 7 (21) | 5 (28) | 2 (13) | .29† |
| ORR | 25 (76) | 13 (72) | 12 (80) | |
| PR | 3 (9) | 2 (11) | 1 (7) | |
| CR | 22 (67) | 11 (61) | 11 (73) | |
| Missing | 1 (3) | 0 (0) | 1 (7) | |
| Response to checkpoint | ||||
| PD | 7 (21) | 1 (6) | 6 (40) | .23† |
| SD | 1 (3) | — | 1 (7) | |
| ORR | 9 (27) | 3 (17) | 6 (40) | |
| PR | 2 (6) | — | 2 (13) | |
| CR | 7 (21) | 3 (17) | 4 (27) | |
| Missing | 16 (48) | 14 (78) | 2 (13) | |
| CRS, any grade§ | ||||
| No | 4 (12) | 1 (6) | 3 (20) | .31‡ |
| Yes | 29 (88) | 17 (94) | 12 (80) | |
| CRS grade ≥3§ | ||||
| No | 31 (94) | 16 (89) | 15 (100) | .49‡ |
| Yes | 2 (6) | 2 (11) | — | |
| NT, any grade§ | ||||
| No | 20 (61) | 11 (61) | 9 (60) | >.99‡ |
| Yes | 13 (39) | 7 (39) | 6 (40) | |
| NT grade ≥3§ | ||||
| No | 24 (72) | 13 (72) | 11 (73) | >.99‡ |
| Yes | 9 (27) | 5 (28) | 4 (27) | |
| Immune mediated toxicity | ||||
| No | 26 (79) | 11 (61) | 15 (100) | >.99‡ |
| Yes | — | — | — | |
| Missing | 7 (21) | 7 (39) | 0 (0) | |
*Wilcoxon rank-sum test.
†Cochran-Armitage test.
‡Fisher's exact test.
§CRS grading by Lee criteria and NT grading by Common Terminology Criteria for Adverse Events in 51%, and by ASTCT in the remaining patients.